Figure 4.

Left ventricular developed pressure (LVDP) recovery, expressed as mmHg, in age matched non-diabetic (ND), Type 2 diabetic (BBZ), BBZ treated with aldose reductase inhibitor (BBZ-ARI), BBZ treated with sorbitol dehydrogenase inhibitor (BBZ-SDI) rat hearts under baseline (A, D) and reperfusion (B, E) conditions. Left ventricular end diastolic pressure (EDP), expressed as mmHg, in ND, BBZ, BBZ-ARI, BBZ-SDI at the end of ischemic period (C, F). Diabetes duration of 12 weeks (A, B, C) (n = 9) and 48 weeks (D, E, F) (n = 6) were used in this study. * P < 0.05 vs ND, BBZ-ARI, and BBZ-SDI within respective diabetes duration matched group comparing LVDP at baseline, ^@ P < 0.05 vs ND, BBZ-ARI, and BBZ-SDI within respective diabetes duration matched group comparing LVDP at reperfusion, ^#P < 0.05 vs ND, BBZ-ARI, and BBZ-SDI within respective diabetes duration matched group comparing End-ischemic EDP.